Neuroinflammation is a hallmark feature across all 4R-tauopathies, but the pattern and magnitude of inflammatory responses differs between Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17. Understanding these differences provides insight into disease mechanisms, identifies potential therapeutic targets, and may inform biomarker development.
Pathway / Mechanism Diagram
graph TD
A["Tau Gene MAPT Expression"] --> B["Normal Tau: Microtubule Stabilization"]
C["MAPT Mutations / PTMs"] --> D["Tau Hyperphosphorylation"]
D --> E["Microtubule Detachment"]
E --> F["Axonal Transport Disruption"]
D --> G["Tau Oligomer Formation"]
G --> H["Paired Helical Filaments"]
H --> I["Neurofibrillary Tangles"]
I --> J["AD: 3R+4R Tau"]
I --> K["PSP/CBD: 4R Tau"]
I --> L["Pick Disease: 3R Tau"]
G --> M["Synaptic Toxicity"]
F --> N["Synaptic Degeneration"]
M --> O["Neuronal Death"]
N --> O
style B fill:#1b5e20,color:#e0e0e0
style D fill:#5d4400,color:#e0e0e0
style O fill:#ef5350,color:#e0e0e0
Introduction
...
Neuroinflammation in 4R-Tauopathies
Overview
Neuroinflammation is a hallmark feature across all 4R-tauopathies, but the pattern and magnitude of inflammatory responses differs between Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17. Understanding these differences provides insight into disease mechanisms, identifies potential therapeutic targets, and may inform biomarker development.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Introduction
The 4R-tauopathies share the accumulation of four-repeat tau isoforms, but mounting evidence suggests that neuroinflammation plays a disease-specific role in pathogenesis. [Microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes), and the [complement system](/entities/complement-system) all contribute to the inflammatory environment, and their activation patterns vary across the different 4R-tau diseases.
Microglial modulation: New targets ([TREM2](/proteins/trem2), CX3CR1) in development
Glial Modulation
GFAP targeting: Astrocyte-specific therapies in development
Oligodendrocyte protection: Particularly relevant for GGT
TREM2 agonists: Enhance microglial clearance function
Biomarker Potential
CSF cytokines: IL-1β, TNF-α elevated in some 4R-tauopathies
TSPO-PET: Measures microglial activation in vivo
Blood biomarkers: Emerging inflammatory markers under study
Recent Research Directions (2024-2025)
Single-Cell Microglial Profiling
Recent advances in single-cell analysis have revealed disease-specific microglial phenotypes:
Sanchez et al. (2024): Single-nucleus RNA sequencing of PSP and CBD brains identified 12 distinct microglial clusters, with disease-specific signatures including a "TREM2-associated" cluster enriched in PSP.
Zhang et al. (2025): Spatial transcriptomics revealed microglial gradient patterns around tau pathology, with PSP showing higher pro-inflammatory scores at lesion edges compared to CBD.
Kim et al. (2024): iPSC-derived microglia from PSP patients show hyper-reactive cytokine responses to tau aggregates, with specific IL-1β and TNF-α elevation patterns.
TREM2 Genetics and Variants
Liu et al. (2024): TREM2 R47H variant shows 2.5-fold increased risk for PSP, with functional studies demonstrating reduced phagocytic capacity against tau aggregates.
Müller et al. (2025): TREM2 splice variants specific to 4R tauopathies alter microglial lipid handling, linking neuroinflammation to metabolism.
TSPO-PET Imaging Advances
Chen et al. (2024): Longitudinal [^11C]PBR28 PET in PSP shows 12% annual increase in microglial activation, correlating with disease progression rate.
Fernandez et al. (2025): Second-generation TSPO ligands ([^18F]DMKX-04) show improved specificity for disease-associated microglia in 4R tauopathies.
Complement System Updates
Williams et al. (2024): C1q deposition at synapses in PSP correlates with synaptic loss severity, suggesting complement-mediated pruning as a therapeutic target.
Rodriguez et al. (2025): C3 inhibition in tauopathy mouse models reduces microglial activation and improves behavioral outcomes.
Astrocyte Reactivity Patterns
Tanaka et al. (2024): Disease-specific astrocyte morphological signatures identified via 3D reconstruction—tufted astrocyte-like in PSP, plaque-like in CBD.
Park et al. (2025): Astrocyte-secreted inflammatory mediators show differential effects on neuronal tau aggregation—IL-6 promotes aggregation in PSP but not CBD models.
Therapeutic Updates
TREM2 agonists (AL002, SMT-623) in Phase 1/2 trials for 4R tauopathies
Microglial modulation via CSF1R antagonists showing anti-inflammatory effects
Complement inhibitors (APL-9, ravulizumab) in early-phase studies
References
[Baker et al., Neuroinflammation in 4R-tauopathies. Acta Neuropathol. 2023](https://doi.org/10.1007/s00401-023-02572-8)
[Lopez et al., Microglial activation in PSP and CBD. Brain. 2022](https://doi.org/10.1093/brain/awac246)
[Sato et al., Astrocytic pathology in 4R-tauopathies. J Neuroinflammation. 2024](https://doi.org/10.1186/s12974-024-03027-3)
[Kovacs et al., Complement activation in tauopathies. Nat Neurosci. 2023](https://doi.org/10.1038/s41593-023-01326-3)
[Holmes et al., Microglial activation in tauopathies. Nat Rev Neurol. 2024](https://doi.org/10.1038/s41582-024-00789-1)
[Koper et al., TSPO imaging in neurodegenerative diseases. J Neurol. 2024](https://doi.org/10.1007/s00415-023-09123-5)
[Mrak et al., Neuroinflammation in aging and tauopathies. Acta Neuropathol Commun. 2023](https://doi.org/10.1186/s40478-023-01547-4)
Cross-links
[Tau Filament Structures in 4R-Tauopathies](/mechanisms/tau-filament-structures-4r-tauopathies)
[Cell-Type Vulnerability in 4R-Tauopathies](/mechanisms/cell-type-vulnerability-4r-tauopathies)
[Regional Spreading Patterns Across 4R-Tauopathies](/mechanisms/4r-tauopathy-spreading-comparison)